Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-08-01
1997-03-11
Chan, Christina
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 2, 530314, 530328, 530402, 530408, 530807, 530816, 530815, 5483611, 435107, 435118, 435121, 435117, 435129, 435128, A61K 3808, C07K 718
Patent
active
056101406
ABSTRACT:
The present invention provides a heterodimeric compound possessing bradykinin and neurokinin receptor antagonist activities useful in the treatment of asthma and other inflammatory diseases especially those involving the airway or pulmonary system. The present invention is also useful in the treatment of pain and inflammation.
REFERENCES:
patent: 4618598 (1986-10-01), Conn
patent: 4894443 (1990-01-01), Greenfield
patent: 5164372 (1992-11-01), Matsuo et al.
Cheronis et al, Recent Progress on Kinins, pp. 551-558, (1992).
Stewart et al, Advances in Expt'l. Med. and Biology, pp. 185-589 (1983).
Vavrek et al, Peptide, Struct. and Funct. Proceedings of the 8.sup.th Am. Pept. Symp. (1983), pp. 381-384.
Kodama et al, European Journal of Pharmacology, vol. 151, pp. 317-320 (1988).
Calixto, et al., "Nonpeptide Bradykinin Antagonists," pp. 97-129 (1991).
Carr, "The Effect of Anti-Inflammatory Drugs on Increased Vascular Permeability Induced by Chemical Mediators," J. Pathology, 108, 1-14 (1972).
Cheronis, et al. "Bradykinin Antagonists: Synthesis and In Vitro Activity of Bissuccinimidoalkane Peptide Dimers," In: Recent Progress in Kinins, pp. 551-558 (1992).
Christopher, T. A., et al., "Beneficial Actions of CP-0127, a Novel Bradykinin Receptor Antagonist, in Murine Traumatic Shock," Am. J. Physiol., 266, H867-H873 (1994).
Desai, M. C., et al., "Discovery of a Potent Substance P Antagonist: Recognition of the Key Molecular Determinant," J. Med. Chem., 35, 4911-4913 (1992).
Hagiwara, D., et al., "Studies on Neurokinin Antagonists. 2. Design and Structure-Activity Relationships of Novel Tripeptide Substance P Antagonists, N.sup..alpha. -[N.sup..alpha. -(N.sup..alpha. -Acetyl-L-Threonyl)-N.sup.1 -Formyl-D-Tryptophyl]-N-methyl-N-(phenyl-methyl)-L-phenylalaninamide and Its Related Compounds," J. Med. Chem., 35, 3184-3191 (1992).
Hagiwara, D., et al., "Studies on Neurokinin Antagonists. 3. Design and Structure-Activity Relationships of New Branched Tripeptides N.sup..alpha. -(Substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as Substance P Antagonists," J. Med. Chem., 36, 2266-2278 (1993).
Kodama, H, et al., "Dimerization of Neurokinin A and B COOH-Terminal Heptapeptide Fragments Enhanced the Selectivity for Tachykinin Receptor Subtypes," Euro. J. Pharmacol., 151, 317-320 (1988).
Stewart, J. M., et al., "Chemistry of Peptide B2 Bradykinin Antagonists," In: Bradykinin Antagonists--Basic and Clinical Research., Burch, R. M. (ed.), Marcel Dekker, Inc., pp. 51-96 (1991).
Stewart, J. M., et al., "Bradykinin Chemistry: Agonists and Antagonists," In: Adv. Exp. Med. Biol., vol. 156, Fritz, H., (ed.), Plenum Press, New York, pp. 585-589 (1983).
Vavrek, R. J., et al., "Succinyl Bis-Bradykinins: Potent Agonists with Exceptional Resistance to Enzymatic Degradation," In: Peptides--Structure and Function, Hruby, V. J., et al., (eds.), Pierce Chemical Company, Rockford.
Goodfellow Val S.
Whalley Eric T.
Wincott Francine E.
Burke John
Chan Christina
Cortech Inc.
Wessendorf T. D.
LandOfFree
Bradykinin receptor antagonists with neurokinin receptor blockin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bradykinin receptor antagonists with neurokinin receptor blockin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bradykinin receptor antagonists with neurokinin receptor blockin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-443576